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tion, all with p<0.01. In CHB patients, MIF, TGF-, IL-17 and ALT
levels were positively correlated (r = 0.725, 0.687, 0.831; p<0.01,
0.05, 0.01, respectively), IL-10 and ALT was negatively correlated
(r = -0.562, p =<0.05). .Multivariate analysis showed that the lev-
els of increment of MIF, TGF- and IL-17 were associated with the
increment of HBV DNA load and severity of liver disease.
Conclusion: There is amarked correlation between the concen-
tration of MIF, TGF- and IL-17 and the severity of liver disease
and viral replication. Increased serum levels of MIF, TGF- and IL-
17 correlate positively with the severity of liver disease and active
viral replication in chronic HBV infection.
http://dx.doi.org/10.1016/j.ijid.2014.03.1081
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Background: Chronic hepatitis B is a serious health problem
worldwide with a substantial minority of patients experiencing
premature death due to end-stage liver disease and/or hepatocel-
luar carcinoma. Antiviral therapy may help prevent complications
of chronic hepatitis B, and seven agents are currently approved
in many countries. Of these agents, ﬁve are nucleos(t)ide analogs
that all have a risk of antiviral drug resistance with long-term
use. Entecavir treatment has signiﬁcantly improved the outcome
of chronic hepatitis B virus (HBV) infection and with a lowest resis-
tance risk. However, it remains largely unknown how immune
systemresponds to the treatment. The aimof thepresent study is to
investigate dynamic ﬂuctuations of serum viral load and Th1/Th2
immunity of chronic hepatitis B patients and their correlation dur-
ing long-term entecavir therapy.
Methods & Materials: Sixty-two patients received entecavir
0.5mg/d therapy. Serum HBVDNA load was measured by Real-
Time-PCR, and the levels of cytokines and T helper 1 (Th1) and
2 (Th2) cytokine producing T-cells by ﬂow cytometry during 260
weeks of the treatment. Multilevel modelling was used to analyse
the relationship between these variables.
Results: Of the 62 patients, all HBeAg positive and with
detectable HBVDNA, the majority (85.6%) had serum levels of
HBVDNA over 107 copies per milliliter. Th1/Th2 cytokines produc-
ingT-cellswere signiﬁcantly lower in chronichepatitis Bpatients as
comparedwith normal individuals. HBV viral load dropped sharply
during the ﬁrst two weeks. In 31 and 48 patients, the level became
undetectable fromweek 24 and 48, respectively. Using pre-therapy
level as the reference, a signiﬁcant increase in Th1/Th2 cytokines
producing T-cells and serum cytokine levels were found from
week 12. These parameters and Th1/Th2 balance steadlly improved
throughout the 260 weeks. Multilevel analyses showed that the
level of decrement of HBVDNA load was associated with the incre-
ment of Th1/Th2 activities only in the later period (12-260 week).
In contrast, Th1/Th2 cytokines producing T-cells remained lower in
one patient detected with entecavir resistant HBV mutation.
Conclusion: Decline of HBVDNA load correlate with increase of
Th1/Th2 immunity in chronic hepatitis B patients during a long-
term treatment with entecavir.
http://dx.doi.org/10.1016/j.ijid.2014.03.1082
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Background:Hepatitis B virus (HBV) andhepatitis C virus (HCV)
infections are among themost common causes of advanced chronic
liver disease worldwide. HBV/HCV co-infection is not uncommon
and the patients with HBV/HCV co-infection have an increased risk
of cirrhosis, hepatocellular carcinoma (HCC), and even death. The
combination of pegylated interferon (Peg-IFN) plus ribavirin (RBV)
is the current standard of care for naïve chronic hepatitis C patients,
achieving a high sustained virological response (SVR) rate. The aim
ofpresent study is toexplore the clinical characteristics ofHBV/HCV
